Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Protein Kinase Inhibitors
  • Pyrroles

abstract

  • The development of sunitinib is a model example of "bench to bedside" work in renal cell carcinoma and may provide a framework for the development of other drugs.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.urolonc.2014.10.012

PubMed ID

  • 25465298

Additional Document Info

start page

  • 275

end page

  • 9

volume

  • 33

number

  • 6